Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials

The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs. Soon, seven different triptans will be clinically available at 13 different oral doses, making evidence-based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-analysis. We wished to provide an evidence-based foundation for using triptans in clinical practice, and to review the methodological issues surrounding triptan trials. We asked pharmaceutical companies and the principal investigators of company-independent trials for the ‘raw patient data’ of all double-blind, randomized, controlled, clinical trials with oral triptans in migraine. All data were cross-checked with published or presented data. We calculated summary estimates across studies for important efficacy and tolerability parameters, and compared these with those from direct, head-to-head, comparator trials. Out of 76 eligible clinical trials, 53 (12 not yet published) involving 24 089 patients met the criteria for inclusion. Mean results (and 95% confidence intervals) for sumatriptan 100 mg, the first available and most widely prescribed oral triptan, are 59% (57-60) for 2 h headache response (improvement from moderate or severe to mild or no pain); 29% (27-30) for 2 h pain free (improvement to no pain); 20% (18-21) for sustained pain free (pain free by 2 h and no headache recurrence or use of rescue medication 2-24 h postdose), and 67% (63-70) for consistency (response in at least two out of three treated attacks); placebo-subtracted proportions for patients with at least one adverse event (AE) are 13% (8-18), for at least one central nervous system AE 6% (3-9), and for at least one chest AE 1.9% (1.0-2.7). Compared with these data: rizatriptan 10 mg shows better efficacy and consistency, and similar tolerability; eletriptan 80 mg shows better efficacy, similar consistency, but lower tolerability; almotriptan 12.5 mg shows similar efficacy at 2 h but better sustained pain-free response, consistency, and tolerability; sumatriptan 25 mg, naratriptan 2.5 mg and eletriptan 20 mg show lower efficacy and better tolerability; zolmitriptan 2.5 mg and 5 mg, eletriptan 40 mg, and rizatriptan 5 mg show very similar results. The results of the 22 trials that directly compared triptans show the same overall pattern. We received no data on frovatriptan, but publicly available data suggest substantially lower efficacy. The major methodological issues involve the choice of the primary endpoint, consistency over multiple attacks, how to evaluate headache recurrence, use of placebo-subtracted proportions to control for across-study differences, and the difference between tolerability and safety. In addition, there are a number of methodological issues specific for direct comparator trials, including encapsulation and patient selection. At marketed doses, all oral triptans are effective and well tolerated. Differences among them are in general relatively small, but clinically relevant for individual patients. Rizatriptan 10 mg, eletriptan 80 mg and almotriptan 12.5 mg provide the highest likelihood of consistent success. Sumatriptan features the longest clinical experience and the widest range of formulations. All triptans are contra-indicated in the presence of cardiovascular disease.

[1]  J. Lance,et al.  Oral sumatriptan in acute migraine , 1991, The Lancet.

[2]  R. Lipton,et al.  Migraine--current understanding and treatment. , 2002, The New England journal of medicine.

[3]  M. Ferrari,et al.  How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. , 1999, Cephalalgia : an international journal of headache.

[4]  G. Gilbert A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. , 1999, Neurology.

[5]  P. Tfelt-Hansen Guidelines for Controlled Trials of Drugs in Migraine. First Edition , 1991 .

[6]  H. Diener,et al.  Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. , 2003, European neurology.

[7]  David Gavaghan,et al.  Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: use of pain intensity and visual analogue scales , 1997, Pain.

[8]  The French Cidp study group,et al.  Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study , 2004, Journal of Neurology.

[9]  A. Zagami 311C90: Long-term efficacy and tolerability profile for the acute treatment of migraine , 1997, Neurology.

[10]  M. Moskowitz,et al.  SUMATRIPTAN: a receptor-targeted treatment for migraine. , 1993, Annual review of medicine.

[11]  N. Cutler,et al.  Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. , 1995, Neurology.

[12]  D McKillop,et al.  Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  J. Lance,et al.  Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. , 1991, European neurology.

[14]  M. Ferrari,et al.  Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. , 1996, Archives of neurology.

[15]  L. Findley,et al.  Sumatriptan in the Treatment of Acute Migraine With Aura , 1992, Cephalalgia : an international journal of headache.

[16]  J. Lance,et al.  Sumatriptan An Oral Dose-Defining Study , 1991 .

[17]  B. Kirkhart,et al.  Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. , 1995, Neurology.

[18]  J. Warner,et al.  Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. , 1999, Current medical research and opinion.

[19]  K. Hoppu,et al.  Sumatriptan for migraine attacks in children , 1997, Neurology.

[20]  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. , 1988, Cephalalgia : an international journal of headache.

[21]  T. Tsuruo,et al.  [Functional involvement of P-glycoprotein in blood-brain barrier]. , 1992, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[22]  N. Santanello,et al.  Determinants of Patient Satisfaction With Migraine Therapy , 2000, Cephalalgia : an international journal of headache.

[23]  P. Goadsby The pharmacology of headache , 2000, Progress in Neurobiology.

[24]  A. Pilgrim Methodology of clinical trials of sumatriptan in migraine and cluster headache. , 1991, European neurology.

[25]  J. Zohar,et al.  Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan , 1998, European Neuropsychopharmacology.

[26]  G. Hirose [Serotonin and migraine]. , 2001, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[27]  L. Fabbri,et al.  [Evaluation of the efficacy of oral sumatriptan in the management of migraine attacks. Clinical results]. , 1995, La Clinica terapeutica.

[28]  R. Lipton,et al.  Within-patient consistency of response of rizatriptan for treating migraine , 2000, Neurology.

[29]  T. M. Brown,et al.  Pathophysiology and Management of the Serotonin Syndrome , 1996, The Annals of pharmacotherapy.

[30]  G. Nappi,et al.  Oral sumatriptan compared with placebo in the acute treatment of migraine , 2004, Journal of Neurology.

[31]  M. Ferrari,et al.  Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.

[32]  J. Feighner,et al.  A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks , 1998, Neurology.

[33]  A. Metz,et al.  Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. , 2001, Clinical therapeutics.

[34]  M. Ferrari,et al.  Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. , 2000, Neurology.

[35]  N. Cutler,et al.  Monitoring of Acute Migraine Attacks: Placebo Response and Safety Data , 1998, Headache.

[36]  B. Colombo,et al.  Acute Treatment of Migraine Attacks: Efficacy and Safety of A Nonsteroidal Anti-Inflammatory Drug, Diclofenac-Potassium, in Comparison To Oral Sumatriptan and Placebo , 1999, Cephalalgia : an international journal of headache.

[37]  T. Olah,et al.  Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. , 1997, British journal of clinical pharmacology.

[38]  S. Diamond The use of sumatriptan in patients on monoamine oxidase inhibitors , 1995, Neurology.

[39]  J. Schoenen,et al.  The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine , 1995, The Lancet.

[40]  P. Goadsby,et al.  The Mode of Action of Sumatriptan is Vascular? A Debate , 1994, Cephalalgia : an international journal of headache.

[41]  L. Fabbri,et al.  High Efficacy and Low Frequency of Headache Recurrence after Oral Sumatriptan , 1995, The Journal of international medical research.

[42]  K. Gruffydd-Jones,et al.  A Within-Patient Comparison of Subcutaneous and Oral Sumatriptan in the Acute Treatment of Migraine in General Practice , 1997, Cephalalgia : an international journal of headache.

[43]  M. Ferrari,et al.  311C90, A new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine , 1996, Neurology.

[44]  A F Cohen,et al.  Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response , 1996, Clinical pharmacology and therapeutics.

[45]  Egilius L H Spierings Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan , 2000, Neurology.

[46]  G. Plosker,et al.  Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. , 1994, Drugs.

[47]  R. Cady The Long‐term Tolerability and Efficacy of Oral Zolmitriptan (Zomig, 31X90) in the Acute Treatment of Migraine. An International Study , 1998 .

[48]  P. Tfelt-Hansen Efficacy and Adverse Events of Subcutaneous, Oral, and Intranasal Sumatriptan Used for Migraine Treatment: A Systematic Review Based on Number Needed To Treat , 1998, Cephalalgia : an international journal of headache.

[49]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[50]  P. Goadsby,et al.  Naratriptan is effective and well tolerated in the acute treatment of migraine. , 1999, Neurology.

[51]  G. Block,et al.  Efficacy and Safety of Rizatriptan Versus Standard Care During Long‐term Treatment for Migraine , 1998 .

[52]  R. Peatfield The Pathophysiology of Headache , 1986 .

[53]  G. Nappi,et al.  Oral Sumatriptan: Effect of a Second Dose, and Incidence and Treatment of Headache Recurrences , 1994, Cephalalgia : an international journal of headache.

[54]  T. Olah,et al.  Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. , 1999, British journal of clinical pharmacology.

[55]  H. Diener,et al.  Headache after frequent use of serotonin agonists zolmitriptan and naratriptan , 1999, The Lancet.

[56]  A J Dowson,et al.  Unbalanced Randomization Influences Placebo Response: Scientific Versus Ethical Issues Around the Use of Placebo in Migraine Trials , 1999, Cephalalgia : an international journal of headache.

[57]  H. Diener,et al.  Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot®) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison , 2002, European Neurology.

[58]  G. Tietjen,et al.  Serotonin Syndrome Complicating Migraine Pharmacotherapy , 1996, Cephalalgia : an international journal of headache.

[59]  J. Graham Pathophysiology of headache. , 1982, Panminerva medica.

[60]  W. Malbecq,et al.  Time-To-Event Analysis, Or Who Gets Better Sooner? an Emerging Concept in Headache Study Methodology , 1999, Cephalalgia : an international journal of headache.

[61]  A. Klassen,et al.  Naratriptan is Effective and Well Tolerated in the Acute Treatment of Migraine. Results of a Double‐Blind, Placebo‐Controlled, Parallel‐Group Study , 1997, Headache.

[62]  G. Lenzi,et al.  Sumatriptan and daily headache. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[63]  L. Hedges,et al.  The Handbook of Research Synthesis , 1995 .

[64]  M. Steinbuch,et al.  Oral and Subcutaneous Sumatriptan in the Acute Treatment of Migraine , 1997, Cephalalgia : an international journal of headache.

[65]  J. Ottervanger,et al.  Characteristics and determinants of sumatriptan-associated chest pain. , 1997, Archives of neurology.

[66]  A. Laurenza,et al.  Naratriptan is effective and well tolerated in the acute treatment of migraine , 1997, Neurology.

[67]  D. Sherman,et al.  Entry and egress of varicella-zoster virus , 1995, Neurology.

[68]  Ferrari,et al.  Eletriptan in acute migraine , 2000, Neurology.

[69]  G. Volans Absorption of Effervescent Aspirin during Migraine , 1974, British medical journal.

[70]  R. Lipton,et al.  Acute Migraine Therapy: Do Doctors Understand What Patients With Migraine Want From Therapy? , 1999 .

[71]  P R Saxena,et al.  Ergotamine in the acute treatment of migraine: a review and European consensus. , 2000, Brain : a journal of neurology.

[72]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Lance,et al.  A Randomized, Double-Blind Comparison of Sumatriptan and Cafergot in the Acute Treatment of Migraine , 1991 .

[74]  R. Lipton,et al.  Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials , 2001, The Lancet.

[75]  M. Ferrari,et al.  Double-Blind, Placebo-Controlled, Dose-Finding Study of Rizatriptan (MK-462) in the Acute Treatment of Migraine , 1997, Cephalalgia : an international journal of headache.

[76]  Dewey K. Ziegler,et al.  Mechanism and Management of Headache , 1995 .

[77]  Giuseppe Orefice,et al.  Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study , 1988, Cephalalgia : an international journal of headache.

[78]  N. Legg,et al.  Comparison of Rizatriptan 10 mg vs. Naratriptan 2.5 mg in Migraine , 1999, European Neurology.

[79]  E. Willoughby,et al.  Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence. A Placebo‐Controlled, Outpatient Study , 1998, Headache.

[80]  C. Lines,et al.  Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in Migraine , 1998, Headache.

[81]  J. Olesen,et al.  Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study , 1998, European journal of neurology.

[82]  S. Aurora,et al.  Efficacy of Zolmitriptan at Early Time-Points for the Acute Treatment of Migraine and Treatment of Recurrence , 2000 .

[83]  N. Ramadan,et al.  Optimizing the dose of zolmitriptan (Zomig,* 311C90) for the acute treatment of migraine , 1997, Neurology.

[84]  A Whitehead,et al.  A general parametric approach to the meta-analysis of randomized clinical trials. , 1991, Statistics in medicine.

[85]  M. Ferrari,et al.  Risk Factors for Headache Recurrence After Sumatriptan: A Study in 366 Migraine Patients , 1996, Cephalalgia : an international journal of headache.

[86]  V. Myllylä,et al.  Tolfenamic Acid Rapid Release Versus Sumatriptan in the Acute Treatment of Migraine: Comparable Effect in a Double‐Blind, Randomized, Controlled, Parallel‐Group Study , 1998, Headache.

[87]  A. Dowson,et al.  A long-term study to maximise migraine relief with zolmitriptan. , 1999, Current medical research and opinion.

[88]  M. Ferrari,et al.  Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan , 1995, Neurology.

[89]  P. Stone,et al.  Tolerability of Sumatriptan: Clinical Trials and Post-Marketing Experience , 2000, Cephalalgia : an international journal of headache.

[90]  P. Rolan,et al.  The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). , 1997, British journal of clinical pharmacology.

[91]  Ferrari,et al.  Guidelines for Controlled Trials of Drugs in Migraine: Second Edition , 2000, Cephalalgia : an international journal of headache.

[92]  J. Olesen,et al.  311C90 (Zolmitriptan), A Novel Centrally and Peripheral Acting Oral 5-Hydroxytryptamine-1D Agonist: A Comparison of Its Absorption During A Migraine Attack and in A Migraine-Free Period , 1996, Cephalalgia : an international journal of headache.

[93]  M. Giacovazzo,et al.  Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of Migraine , 1998, Headache.

[94]  J. Askenasy,et al.  A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. , 1992, European neurology.

[95]  N. Ramadan,et al.  Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine , 1997, Neurology.

[96]  H. Wolff,et al.  Wolff's headache and other head pain , 1987 .

[97]  N. Mathew,et al.  A Long‐term Open‐Label Study of Oral Almotriptan 12.5 mg for the Treatment of Acute Migraine , 2002, Headache.

[98]  R. Moore,et al.  Using Numerical Results from Systematic Reviews in Clinical Practice , 1997, Annals of Internal Medicine.

[99]  E. Willoughby,et al.  Efficacy and Safety of Rizatriptan Wafer for the Acute Treatment of Migraine , 1999 .

[100]  V. Pfaffenrath,et al.  Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral Sumatriptan , 1998, Headache.

[101]  A. Korczyn,et al.  Zolmitriptan provides consistent migraine relief when used in the long-term. , 1999, Current medical research and opinion.

[102]  A. Dowson,et al.  How Does Almotriptan Compare With Other Triptans? A Review of Data From Placebo‐Controlled Clinical Trials , 2002, Headache.

[103]  P. Rolan,et al.  The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. , 1996, British journal of clinical pharmacology.

[104]  H. Diener [Sumatriptan in the treatment of acute migraine attacks]. , 1993, Der Internist.

[105]  V. Pfaffenrath [Treatment of migraine attacks with sumatriptan]. , 1993, Fortschritte der Medizin.

[106]  B. Jamerson,et al.  Oral sumatriptan for the long-term treatment of migraine: clinical findings. , 1995, Neurology.